The effect of synthetic retinoid, Am80, on T helper cell development and antibody production in murine collagen-induced arthritis

Modern Rheumatology

Volumn 20, Issue 3, 2010, Pages 244-251

  Sato, Aya ^a   Watanabe, Kaori ^a   Kaneko, Kayoko ^a   Murakami, Yousuke ^a   Ishido, Miwako ^a   Miyasaka, Nobuyuki ^a   Nanki, Toshihiro ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Am80; Collagen induced arthritis; Retinoid; Th1; Th17

Indexed keywords

BENZOIC ACID DERIVATIVE; RETINOID; TAMIBAROTENE; TETRALIN DERIVATIVE;

ANIMAL; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; CELL DIFFERENTIATION; DBA MOUSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HOSPITALIZATION; IMMUNOLOGY; JOINT; MALE; MOUSE;

ANIMALS; ANTIBODY FORMATION; ARTHRITIS, EXPERIMENTAL; BENZOATES; CELL DIFFERENTIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; JOINTS; MALE; MICE; MICE, INBRED DBA; RETINOIDS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, HELPER-INDUCER; TETRAHYDRONAPHTHALENES;

EID: 77956637629     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0265-y     Document Type: Article

References (43)

1. Hashimoto Y. Retinobenzoic acids and nuclear retinoic acid receptors. Cell Struct Funct. 1991;16:113-23.
2. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10:940-54. (Pubitemid 26285969)
3. Sporn MB, Roberts AB. Cervical dysplasia regression induced by all-trans-retinoic acid. J Natl Cancer Inst. 1994;86:476-7. (Pubitemid 24111001)
4. Beehler BC, Brinckerhoff CE, Ostrowski J. Selective retinoic acid receptor ligands for rheumatoid arthritis. Curr Opin Investig Drugs. 2004;5:1153-7. (Pubitemid 39545283)
5. Kang BY, Chung SW, Kim SH, Kang SN, Choe YK, Kim TS. Retinoid-mediated inhibition of interleukin-12 production in mouse macrophages suppresses Th1 cytokine profile in CD4+ T cells. Br J Pharmacol. 2000;130:581-6. (Pubitemid 30332976)
6. 1/2 pathway independently of RAR activation. Arthritis Res Ther. 2008;10:R141.
7. Pino-Lagos K, Benson MJ, Noelle RJ. Retinoic acid in the immune system. Ann N Y Acad Sci. 2008;1143:170-87.
8. Hoag KA, Nashold FE, Goverman J, Hayes CE. Retinoic acid enhances the T helper 2 cell development that is essential for robust antibody responses through its action on antigen-presenting cells. J Nutr. 2002;132:3736-9. (Pubitemid 35435055)
9. Iwata M, Eshima Y, Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol. 2003;15:1017-25. (Pubitemid 36987299)
10. Schambach F, Schupp M, Lazar MA, Reiner SL. Activation of retinoic acid receptor-a favours regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation. Eur J Immunol. 2007;37:2396-9. (Pubitemid 47423609)
11. Elias KM, Laurence A, Davidson TS, Stephens G, Kanno Y, Shevach EM, et al. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood. 2008;111:1013-20. (Pubitemid 351213378)
12. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317:256-60. (Pubitemid 47076203)
13. + memory T cells in rheumatoid arthritis synovium. Arthritis Res. 2000;2:415-23.
14. + T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:1669-76.
15. Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi JI, Kaibara N, et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:1299-304.
16. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42:963-70. (Pubitemid 29215007)
17. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005;7:R784-95.
18. Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood. 1997;90:967-73. (Pubitemid 27314129)
19. Miwako I, Kagechika H. Tamibarotene. Drugs Today (Barc). 2007;43:563-8. (Pubitemid 47529739)
20. Ohnishi K. PML-RARa inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol. 2007;12:313-7. (Pubitemid 47573414)
21. Kuwabara K, Shudo K, Hori Y. Novel synthetic retinoic acid inhibits rat collagen arthritis and differentially affects serum immunoglobulin subclass levels. FEBS Lett. 1996;378:153-6. (Pubitemid 26015564)
22. Takeda N, Manabe I, Shindo T, Iwata H, Iimuro S, Kagechika H, et al. Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6. Arterioscler Thromb Vasc Biol. 2006;26:1177-83. (Pubitemid 43732130)
23. Kagechika H. Novel synthetic retinoids and separation of the pleiotropic retinoidal activities. Curr Med Chem. 2002;9:591-608. (Pubitemid 34436436)
24. Ohyanagi N, Ishido M, Suzuki F, Kaneko K, Kubota T, Miyasaka N, et al. Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo. Arthritis Rheum. 2009;60:3118-27.
25. Klemann C, Raveney BJ, Klemann AK, Ozawa T, von Horsten S, Shudo K, et al. Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis. Am J Pathol. 2009;174(6):2234-45.
26. Nagai H, Matsuura S, Bouda K, Takaoka Y, Wang T, Niwa S, et al. Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice. Pharmacology. 1999;58:101-12. (Pubitemid 29022954)
27. Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T. Effect of a small molecule inhibitor of nuclear factor-κB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther. 2005;7:R1348-59.
28. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004;50:650-9. (Pubitemid 38198849)
29. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002;46:802-5. (Pubitemid 34214263)
30. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171:6173-7. (Pubitemid 37467240)
31. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-32.
32. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133-41. (Pubitemid 41541791)
33. Manoury-Schwartz B, Chiocchia G, Bessis N, Abehsira-Amar O, Batteux F, Muller S, et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol. 1997;158:5501-6. (Pubitemid 127681259)
34. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol. 1997;158:5507-13. (Pubitemid 127681260)
35. Sarkar S, Cooney LA, White P, Dunlop DB, Endres J, Jorns JM, et al. Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Res Ther. 2009;11:R158.
36. Mohty M, Morbelli S, Isnardon D, Sainty D, Arnoulet C, Gaugler B, et al. All-trans retinoic acid skews monocyte differentiation into interleukin-12- secreting dendritic-like cells. Br J Haematol. 2003;122:829-36. (Pubitemid 37100312)
37. Wei J, Duramad O, Perng OA, Reiner SL, Liu YJ, Qin FX. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci USA. 2007;104:18169-74. (Pubitemid 350210839)
38. + Tregs. J Clin Invest. 2006;116:2434-41.
39. Nozaki Y, Yamagata T, Sugiyama M, Ikoma S, Kinoshita K, Funauchi M. Anti-inflammatory effect of all-trans-retinoic acid in inflammatory arthritis. Clin Immunol. 2006;119:272-9.
40. Tokuyama H, Tokuyama Y. The regulatory effects of all-transretinoic acid on isotype switching: retinoic acid induces IgA switch rearrangement in cooperation with IL-5 and inhibits IgG1 switching. Cell Immunol. 1999;192:41-7. (Pubitemid 29133837)
41. Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 1998;41:2117-21. (Pubitemid 29009369)
42. Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 2008;58:3710-9.
43. Nagpal S, Cai J, Zheng T, Patel S, Masood R, Lin GY, et al. Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma. Mol Cell Biol. 1997;17:4159-68. (Pubitemid 27281892)